CytoDyn of Lutz, Florida, a development stage biotechnology company focused on the development of new therapies for combating infection with immune deficiency virus and other antibody applications, has entered into an asset purchase agreement, effective July 25, 2012, to acquire from Progenics its proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140.

“We believe that adding PRO 140 to our pipeline of potential anti-viral therapeutics along with Cytolin®, which we are already developing, will position the Company as one of the leading companies in the development of monoclonal antibody-based therapies for HIV/AIDS,” commented Gregory A. Gould, Chairman of the Board. “We intend to move forward with the necessary clinical trials to bring both of these potential treatments for HIV to market; and, if we are successful in the development of one or both of these therapies, this could lead to a paradigm shift in the treatment of HIV/AIDS with significant benefits for patients worldwide.”

Leave a Reply

Your email address will not be published. Required fields are marked *